For: | Lee HJ, Yeon JE, Ko EJ, Yoon EL, Suh SJ, Kang K, Kim HR, Kang SH, Yoo YJ, Je J, Lee BJ, Kim JH, Seo YS, Yim HJ, Byun KS. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21(45): 12787-12799 [PMID: 26668503 DOI: 10.3748/wjg.v21.i45.12787] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i45/12787.htm |
Number | Citing Articles |
1 |
Amanda Karolina Soares Silva, Christina Alves Peixoto. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation. Cellular and Molecular Life Sciences 2018; 75(16): 2951 doi: 10.1007/s00018-018-2838-4
|
2 |
Lourdes Román-Malo, Pedro Bullon. Influence of the Periodontal Disease, the Most Prevalent Inflammatory Event, in Peroxisome Proliferator-Activated Receptors Linking Nutrition and Energy Metabolism. International Journal of Molecular Sciences 2017; 18(7): 1438 doi: 10.3390/ijms18071438
|
3 |
Danping Zheng, Lara Kern, Eran Elinav. The NLRP6 inflammasome. Immunology 2021; 162(3): 281 doi: 10.1111/imm.13293
|
4 |
Dilinare Abdurehman, Yindengzhi Guoruoluo, Xueying Lu, Jun Li, Rahima Abudulla, Geyu Liu, Xuelei Xin, Haji Akber Aisa. Optimization of preparation method of hepatoprotective active components from Coreopsis tinctoria Nutt. and its action mechanism in vivo. Biomedicine & Pharmacotherapy 2023; 167: 115590 doi: 10.1016/j.biopha.2023.115590
|
5 |
Luisa Vonghia, Mikhaïl A. Van Herck, Jonas Weyler, Sven Francque. Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease. Frontiers in Immunology 2019; 10 doi: 10.3389/fimmu.2019.00563
|
6 |
Yoon-Mi Han, Yong-Jik Lee, Yoo-Na Jang, Hyun-Min Kim, Hong Seog Seo, Tae Woo Jung, Ji Hoon Jeong, Luis Loura. Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPARδ‐AMPK‐PGC‐1α Pathway in Dyslipidemic Conditions. BioMed Research International 2020; 2020(1) doi: 10.1155/2020/7806860
|
7 |
Hossein Pazoki, Hamed Mirjalali, Maryam Niyyati, Seyed Javad Seyed Tabaei, Nariman Mosaffa, Shabnam Shahrokh, Hamid Asadzadeh Ahdaei, Andreas Kupz, Mohammad Reza Zali. Toxoplasma gondii profilin induces NLRP3 activation and IL-1β production/secretion in THP-1 cells. Microbial Pathogenesis 2023; 180: 106120 doi: 10.1016/j.micpath.2023.106120
|
8 |
Jia Wang, Lei Wang, Xiao-Jing Zhang, Peng Zhang, Jingjing Cai, Zhi-Gang She, Hongliang Li. Recent updates on targeting the molecular mediators of NAFLD. Journal of Molecular Medicine 2023; 101(1-2): 101 doi: 10.1007/s00109-022-02282-4
|
9 |
Sarang Tartey, Thirumala‐Devi Kanneganti. Differential role of the NLRP3 inflammasome in infection and tumorigenesis. Immunology 2019; 156(4): 329 doi: 10.1111/imm.13046
|
10 |
Marcelle de Carvalho Ribeiro, Gyongyi Szabo. Role of the Inflammasome in Liver Disease. Annual Review of Pathology: Mechanisms of Disease 2022; 17(1): 345 doi: 10.1146/annurev-pathmechdis-032521-102529
|
11 |
Congjian Shi, Hongqin Yang, Zhenghong Zhang. Involvement of Nucleotide-Binding Oligomerization Domain-Like Receptor Family Pyrin Domain Containing 3 Inflammasome in the Pathogenesis of Liver Diseases. Frontiers in Cell and Developmental Biology 2020; 8 doi: 10.3389/fcell.2020.00139
|
12 |
Peng-Fei Wang, Zhen-Guang Li, Yong Zhang, Xiao-Hua Ju, Xin-Wu Liu, Ai-Ming Zhou, Jing Chen. NLRP6 Inflammasome Ameliorates Brain Injury after Intracerebral Hemorrhage. Frontiers in Cellular Neuroscience 2017; 11 doi: 10.3389/fncel.2017.00206
|
13 |
Jingjing Cai, Xiao-Jing Zhang, Hongliang Li. Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease. Trends in Endocrinology & Metabolism 2018; 29(10): 712 doi: 10.1016/j.tem.2018.08.003
|
14 |
Maayan Levy, Hagit Shapiro, Christoph A. Thaiss, Eran Elinav. NLRP6: A Multifaceted Innate Immune Sensor. Trends in Immunology 2017; 38(4): 248 doi: 10.1016/j.it.2017.01.001
|
15 |
Mohammad Zarei, David Aguilar-Recarte, Xavier Palomer, Manuel Vázquez-Carrera. Revealing the role of peroxisome proliferator-activated receptor β/δ in nonalcoholic fatty liver disease. Metabolism 2021; 114: 154342 doi: 10.1016/j.metabol.2020.154342
|
16 |
Hoda El Aggan, Sabah Mahmoud, Nevine El Deeb, Islam Eleishi, Assem El-Shendidi. Significance of elevated serum and hepatic NOD-like receptor pyrin domain containing 3 (NLRP3) in hepatitis C virus-related liver disease. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-22022-5
|
17 |
Mojdeh Khosravi, Hanieh Mohammad Rahimi, Abdoreza Nazari, Kaveh Baghaei, Hamid Asadzadeh Aghdaei, Shabnam Shahrokh, Meysam Sharifdini, Ana Claudia Torrecilhas, Fatemeh Mehryab, Hamed Mirjalali, Faezeh Shekari, Mohammad Reza Zali. Characterisation of extracellular vesicles isolated from hydatid cyst fluid and evaluation of immunomodulatory effects on human monocytes. Journal of Cellular and Molecular Medicine 2023; 27(17): 2614 doi: 10.1111/jcmm.17894
|
18 |
Michael Eisenhut. In diabetic ketoacidosis brain injury including cerebral oedema and infarction is caused by interleukin-1. Medical Hypotheses 2018; 121: 44 doi: 10.1016/j.mehy.2018.09.005
|
19 |
Anthos Christofides, Eirini Konstantinidou, Chinmay Jani, Vassiliki A. Boussiotis. The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metabolism 2021; 114: 154338 doi: 10.1016/j.metabol.2020.154338
|
20 |
Nicolas Quezada, Ilse Valencia, Javiera Torres, Gregorio Maturana, Jaime Cerda, Juan Pablo Arab, Juan José Fuentes, Claudio Pinto, Dannae Turiel, Victor Cortés. Insulin resistance and liver histopathology in metabolically unhealthy subjects do not correlate with the hepatic abundance of NLRP3 inflammasome nor circulating IL-1β levels. BMJ Open Diabetes Research & Care 2021; 9(1): e001975 doi: 10.1136/bmjdrc-2020-001975
|
21 |
Nahum Méndez-Sánchez, Shreya C. Pal, Jacqueline Córdova-Gallardo. How far are we from an approved drug for nonalcoholic steatohepatitis?. Expert Opinion on Pharmacotherapy 2023; 24(9): 1021 doi: 10.1080/14656566.2023.2206953
|
22 |
Laxman Ghimire, Sagar Paudel, Liliang Jin, Samithamby Jeyaseelan. The NLRP6 inflammasome in health and disease. Mucosal Immunology 2020; 13(3): 388 doi: 10.1038/s41385-020-0256-z
|
23 |
Jiayu He, Chunlin Huang, Li Kong, You Huang, Zhaoping Ou, Mingqi Yang, Jiao Wu, Yu Yang, Huan Yao, Jine Yi, Shuiping Liu. Betulinic acid mitigates lipopolysaccharide-induced intestinal injury of weaned piglets through modulation of the mitochondrial quality control. International Immunopharmacology 2025; 148: 114097 doi: 10.1016/j.intimp.2025.114097
|
24 |
Hossein Pazoki, Hanieh Mohammad Rahimi, Hamed Mirjalali, Maryam Niyyati, Nariman Mosaffa, Seyed Javad Seyed Tabaei, Shabnam Shahrokh, Hamid Asadzadeh Aghdaei, Mohammad Reza Zali. Soluble total antigen derived from Toxoplasma gondii tachyzoites increased the expression levels of NLRP1, NLRP3, NLRC4, AIM2, and the release of mature form of IL1β, but downregulated the expression of IL1β and IL18 genes in THP-1cell line. Microbial Pathogenesis 2021; 158: 105072 doi: 10.1016/j.micpath.2021.105072
|
25 |
Tara Man Kadayat, Aarajana Shrestha, Yong Hyun Jeon, Hongchan An, Jina Kim, Sung Jin Cho, Jungwook Chin. Targeting Peroxisome Proliferator-Activated Receptor Delta (PPARδ): A Medicinal Chemistry Perspective. Journal of Medicinal Chemistry 2020; 63(18): 10109 doi: 10.1021/acs.jmedchem.9b01882
|
26 |
Xin Meng, Lin Wang, Yan-Chao Du, Dong Cheng, Tao Zeng. PPARβ/δ as a promising molecular drug target for liver diseases: A focused review. Clinics and Research in Hepatology and Gastroenterology 2024; 48(6): 102343 doi: 10.1016/j.clinre.2024.102343
|
27 |
Pankaj Aggarwal, Tamneet Singh, Naim Alkhouri. Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root. Current Hepatology Reports 2020; 19(3): 302 doi: 10.1007/s11901-020-00533-x
|
28 |
Linfang Chen, Liujun Xue, Jinlong Zheng, Xiangyang Tian, Yingdong Zhang, Qiang Tong. PPARß/δ agonist alleviates NLRP3 inflammasome-mediated neuroinflammation in the MPTP mouse model of Parkinson’s disease. Behavioural Brain Research 2019; 356: 483 doi: 10.1016/j.bbr.2018.06.005
|
29 |
Se-Yun Cheon, Kyung-Sook Chung, Kyung-Jin Lee, Ho-Young Choi, In-Hye Ham, Dong-Hoon Jung, Yun-Yeop Cha, Hyo-Jin An. HVC1 ameliorates hyperlipidemia and inflammation in LDLR−/− mice. BMC Complementary and Alternative Medicine 2017; 17(1) doi: 10.1186/s12906-017-1734-z
|
30 |
Antje Bruckbauer, Jheelam Banerjee, Lizhi Fu, Fenfen Li, Qiang Cao, Xin Cui, Rui Wu, Hang Shi, Bingzhong Xue, Michael B. Zemel. A Combination of Leucine, Metformin, and Sildenafil Treats Nonalcoholic Fatty Liver Disease and Steatohepatitis in Mice. International Journal of Hepatology 2016; 2016: 1 doi: 10.1155/2016/9185987
|
31 |
Liangzheng Chang, Yuying Tian, Lei Xu, Qiuyao Hao, Lingyu Song, Yinying Lu, Yunhuan Zhen, Dunfang Zhang. Spotlight on NLRP6 and Tumor Research Situation: A Potential Cancer Participant. Journal of Immunology Research 2023; 2023: 1 doi: 10.1155/2023/6613064
|
32 |
Xiaqiong Mao, Jingjing Ma, Chunhua Jiao, Nana Tang, Xiaojing Zhao, Di Wang, Yue Zhang, Ziping Ye, Chenjing Xu, Jingyue Jiang, Shasha Wu, Xiufang Cui, Hongjie Zhang, Xinyun Qiu. Faecalibacterium prausnitzii Attenuates DSS‐Induced Colitis by Inhibiting the Colonization and Pathogenicity of Candida albicans. Molecular Nutrition & Food Research 2021; 65(21) doi: 10.1002/mnfr.202100433
|
33 |
Ahmad Alatshan, Szilvia Benkő. Nuclear Receptors as Multiple Regulators of NLRP3 Inflammasome Function. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.630569
|
34 |
Giuliana Muzio, Giuseppina Barrera, Stefania Pizzimenti. Peroxisome Proliferator-Activated Receptors (PPARs) and Oxidative Stress in Physiological Conditions and in Cancer. Antioxidants 2021; 10(11): 1734 doi: 10.3390/antiox10111734
|
35 |
Guillaume Wettstein, Jean‐Michel Luccarini, Laurence Poekes, Patrick Faye, Francine Kupkowski, Vanessa Adarbes, Evelyne Defrêne, Céline Estivalet, Xavier Gawronski, Ingrid Jantzen, Alain Philippot, Julien Tessier, Pascale Tuyaa‐Boustugue, Fiona Oakley, Derek A. Mann, Isabelle Leclercq, Sven Francque, Irena Konstantinova, Pierre Broqua, Jean‐Louis Junien. The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis. Hepatology Communications 2017; 1(6): 524 doi: 10.1002/hep4.1057
|
36 |
Andreea-Manuela Mirea, Cees J. Tack, Triantafyllos Chavakis, Leo A.B. Joosten, Erik J.M. Toonen. IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies. Trends in Molecular Medicine 2018; 24(5): 458 doi: 10.1016/j.molmed.2018.03.005
|
37 |
Yaping Wang, Takero Nakajima, Frank J. Gonzalez, Naoki Tanaka. PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice. International Journal of Molecular Sciences 2020; 21(6): 2061 doi: 10.3390/ijms21062061
|
38 |
Joseph Adu-Amankwaah, Adebayo Oluwafemi Adekunle, Ziqing Tang, Aisha Bushi, Rubin Tan, Lu Fu, Zheng Gong, Ziyu Ma, Richard Mprah, Marie Louise Ndzie Noah, Prosperl Ivette Wowui, Jeremiah Ong'achwa Machuki, Xiuhua Pan, Tao Li, Hong Sun. Estradiol contributes to sex differences in resilience to sepsis-induced metabolic dysregulation and dysfunction in the heart via GPER-1-mediated PPARδ/NLRP3 signaling. Metabolism 2024; 156: 155934 doi: 10.1016/j.metabol.2024.155934
|
39 |
Zeinab Mokhtari, Deanna L Gibson, Azita Hekmatdoost. Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. Advances in Nutrition 2017; 8(2): 240 doi: 10.3945/an.116.013151
|
40 |
Jin Kyung Kim, Hyo Sun Jin, Hyun‐Woo Suh, Eun‐Kyeong Jo. Negative regulators and their mechanisms in NLRP3 inflammasome activation and signaling. Immunology & Cell Biology 2017; 95(7): 584 doi: 10.1038/icb.2017.23
|
41 |
Lin Xiao, Jing-Hui Dong, Xu Teng, Sheng Jin, Hong-Mei Xue, Shang-Yu Liu, Qi Guo, Wei Shen, Xiao-Chen Ni, Yu-Ming Wu. Hydrogen sulfide improves endothelial dysfunction in hypertension by activating peroxisome proliferator-activated receptor delta/endothelial nitric oxide synthase signaling. Journal of Hypertension 2018; 36(3): 651 doi: 10.1097/HJH.0000000000001605
|
42 |
Yasmine Sebti, Lise Ferri, Mathilde Zecchin, Justine Beauchamp, Denis Mogilenko, Bart Staels, Hélène Duez, Benoit Pourcet. Lipid-Activated Nuclear Receptors. Methods in Molecular Biology 2019; 1951: 189 doi: 10.1007/978-1-4939-9130-3_15
|
43 |
Jiashu Pan, Wenjun Zhou, Ruohui Xu, Lianjun Xing, Guang Ji, Yanqi Dang. Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease. Biomedicine & Pharmacotherapy 2022; 151: 113127 doi: 10.1016/j.biopha.2022.113127
|
44 |
Peishan Wu, Xiaolei Wang. Natural Drugs: A New Direction for the Prevention and Treatment of Diabetes. Molecules 2023; 28(14): 5525 doi: 10.3390/molecules28145525
|
45 |
Francque Sven M., Bedossa Pierre, Abdelmalek Manal F., Anstee Quentin M., Bugianesi Elisabetta, Ratziu Vlad, Huot-Marchand Philippe, Scherrer Bruno, Junien Jean-Louis, Broqua Pierre, Abitbol Jean-Louis. A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study. Contemporary Clinical Trials 2020; 98: 106170 doi: 10.1016/j.cct.2020.106170
|
46 |
Taofeek O. Usman, Emmanuel D. Areola, Olufunto O. Badmus, InKyeom Kim, Lawrence A. Olatunji. Sodium acetate and androgen receptor blockade improve gestational androgen excess-induced deteriorated glucose homeostasis and antioxidant defenses in rats: roles of adenosine deaminase and xanthine oxidase activities. The Journal of Nutritional Biochemistry 2018; 62: 65 doi: 10.1016/j.jnutbio.2018.08.018
|
47 |
Huicun Zhang, Xiang Gao, Pengmin Chen, Hongbing Wang. Protective Effects of Tiaoganquzhi Decoction in Treating inflammatory Injury of Nonalcoholic Fatty liver Disease by Promoting CGI-58 and Inhibiting Expression of NLRP3 Inflammasome. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.851267
|
48 |
Guglielmina Chimienti, Antonella Orlando, Francesco Russo, Benedetta D’Attoma, Manuela Aragno, Eleonora Aimaretti, Angela Maria Serena Lezza, Vito Pesce. The Mitochondrial Trigger in an Animal Model of Nonalcoholic Fatty Liver Disease. Genes 2021; 12(9): 1439 doi: 10.3390/genes12091439
|
49 |
Tommaso Mello, Maria Materozzi, Andrea Galli. PPARs and Mitochondrial Metabolism: From NAFLD to HCC. PPAR Research 2016; 2016: 1 doi: 10.1155/2016/7403230
|
50 |
Kirstine S. Tølbøl, Birgit Stierstorfer, Jörg F. Rippmann, Sanne S. Veidal, Kristoffer T. G. Rigbolt, Tanja Schönberger, Matthew P. Gillum, Henrik H. Hansen, Niels Vrang, Jacob Jelsing, Michael Feigh, Andre Broermann. Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences 2019; 64(5): 1238 doi: 10.1007/s10620-018-5395-7
|
51 |
Hélène Duez, Benoit Pourcet. Nuclear Receptors in the Control of the NLRP3 Inflammasome Pathway. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.630536
|
52 |
Jina Kim, Tara Man Kadayat, Jae-Eon Lee, Sugyeong Kwon, Kyungjin Jung, Ji Sun Hwang, Oh-bin Kwon, Ye Jin Kim, Yeon-Kyung Choi, Keun-Gyu Park, Hayoung Hwang, Sung Jin Cho, Taeho Lee, Yong Hyun Jeon, Jungwook Chin. Discovery of the therapeutic potential of PPARδ agonist bearing 1,3,4- thiadiazole in inflammatory disorders. European Journal of Medicinal Chemistry 2024; 279: 116856 doi: 10.1016/j.ejmech.2024.116856
|